Dynavax Technologies Corporation is a drug manufacturers - specialty & generic business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.33 – an increase of 4.71% over the previous week. Dynavax Technologies Corporation employs 405 staff and has a trailing 12-month revenue of around $277.2 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.33 |
|---|---|
| 52-week range | $9.74 - $14.63 |
| 50-day moving average | $12.86 |
| 200-day moving average | $12.07 |
| Wall St. target price | $24.25 |
| PE ratio | 54.1 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.20 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.48 from 2025-05-01
| 1 week (2025-04-25) | 6.10% |
|---|---|
| 1 month (2025-04-04) | -9.25% |
| 3 months (2025-02-04) | -11.69% |
| 6 months (2024-11-04) | -2.63% |
| 1 year (2024-05-03) | -2.21% |
|---|---|
| 2 years (2023-05-03) | 4.17% |
| 3 years (2022-05-03) | 25.46% |
| 5 years (2020-05-01) | 173.33% |
Valuing Dynavax Technologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dynavax Technologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dynavax Technologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Dynavax Technologies Corporation shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Dynavax Technologies Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.5 million.
The EBITDA is a measure of a Dynavax Technologies Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $277.2 million |
|---|---|
| Operating margin TTM | 0.8% |
| Gross profit TTM | $169 million |
| Return on assets TTM | 0.06% |
| Return on equity TTM | 4.48% |
| Profit margin | 9.85% |
| Book value | $4.76 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.
Dynavax Technologies Corporation's shares were split on a 1:10 basis on 9 November 2014 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.
Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $9.74 up to $14.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.263. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U. S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.